Phage therapy: progress in pharmacokinetics

Muhammad Imran Qadir*, Tahira Moeen, Ardas Masood

Institute of Molecular Biology & Biotechnology, Bahauddin Zakariya University, Multan, Pakistan

The concept of phage therapy exists in the history and it has been ignored for a long time, but the consequence of drug resistance in pathogen bacteria has forced the forgotten kingdom of phage therapy to be re-explored. However, for the successful implementation and acceptance of phage therapy worldwide, the number of factors need to be addressed. In pharmacology of phage therapy, pharmacodynamics is a straightforward concept, on the other hand, owing to the unique feature of phages to replicate and their high sensitivity, pharmacokinetics is rather complex. In this review, we have discussed pharmacokinetics and some recent advances in delivery systems as to achieve the therapeutically effective concentrations of phage in their activated form.

Keywords: Phage therapy/pharmacology. Pharmacokinetics. Delivery systems

INTRODUCTION

Bacterial resistance against antibiotics has considerably peaked in recent years; the menace of resistance has given birth to a new range of extended spectrum pathogens. The failure of antibiotic and chemotherapy for eradication of bacteria has forced scientists to look for alternative biological methods. One such approach is the use of lytic bacteriophages against pathogen bacteria. Felix d’Hérelle, the discoverer of bacteriophages, first introduced the idea of phage therapy in the beginning of the 20th century (Sulakvelidze, 2005). However, the initial trials of phage therapy produced inconsistent results to be considered over antibiotics. Even though, some US pharmaceutical companies produced some commercial phage products in 1930s. Subsequently, the Soviet Union developed phage therapy against diseases like diarrhea and wound infections (Sulakvelidze, Alavidze, Morris, 2001). In Russia, several phage formulations are now being sold as registered medicine.

Phage therapy to combat bacterial infections is garnering attention for the second time in 100 years, but solid clinical support for its widespread use is still lacking. Before proper human clinical trial of phage therapy can be considered, there are a number of issues that are considered necessary to be addressed (Knoll, Mylonakis, 2014). There are multiple factors that direct the therapeutic efficacy of phage therapy, for example, for convenient oral application; the phage must endure gastrointestinal route. Furthermore, phage should stay for a sufficient period of time and reach the infected tissue with high enough titer to achieve its lytic activity. Moreover, for safety, phage particles should not impose any side effects and must not carry any virulence gene, as they might get transferred to the target host.

The process of using phages for therapy is conceptually simple; although, along with the simplicity comes the consequences of a certain degree i.e. complex pharmacokinetics. This complexity is the phages’ ability to replicate their number, which is a result of antibacterial activity, precisely where target bacteria are present. As with any antimicrobial agent, the key step is to reach bacterial targets in enough loads to ensure that a minimum active concentration is achieved. This can be attained either through the direct application of phages to the infection site or via systemic delivery (Chan, Abedon, Loc-Carrillo, 2013).

Phage therapy pharmacokinetics

There is a handful of data that entails pharmacology of bacteriophage therapy, with a very few that emphasize on the pharmacokinetics of phage therapy. Pharmacology deals with the drug and body interactions, it is subdivided

*Correspondence: M. I. Qadir. Institute of Molecular Biology & Biotechnology, Bahauddin Zakariya University, Multan, Pakistan-6000. Phone: +92-301-6515613. E-mail: mrimranqadir@hotmail.com
in pharmacokinetics-body’s impact on drug- and pharmacodynamics-drugs impact on the body.

Pharmacokinetics accounts for a drug’s ability to reach sufficient concentrations in the locality of targeted tissues, as it is very important to bring about the pharmacodynamic effects of the drug. This pharmacokinetics summarizes into absorption, distribution, metabolism and excretion. Absorption is drug movement into the blood. From the blood the drug is transported to the body tissues this phenomenon is known as distribution. Once reached the target tissues, the drug is metabolized and modified into its active form, the last step is excretion of drugs from the body. All these pharmacokinetic features play their role in both increasing and reducing drug densities. For example, both absorption and distribution result in the decrease in drug densities owing to drug dilution, which at the same time might increases drug density in the particular body organ (Abedon et al., 2011). Depending upon the pharmacokinetics different means of drug delivery are adopted. The delivery route of a drug is selected on a number of factors; a) target tissue, b) sensitivity of drug to body enzymes, immunity, pH etc) drug in take routine, d) patient’s convenience.

In phage therapy, metabolism can work two ways; either inactivation of phage particles due to contact with the immune system or activation followed by replication of phages. Moreover, excretion results in decreased drug densities, the other way round, it can serve to increase phage concentration in organs like kidney and bladder, which may prove therapeutically beneficial (Vandenheuvel, Lavigne, Brüssow, 2015).

Whatever the case may be, the success of phage therapy depends on enough phage generations in the locality of the target to bring about the eradication of pathogen bacteria from the body. The increase in phage concentration to sufficient densities can be attained by two means. Firstly, with in situ replication, that is called active treatment, or as a result of pharmacologically conventional dosing, the passive treatment. The ways of rising phage concentration must be adequately stout so that they compensate the mechanism of phage reduction. The goal is thus to achieve minimum phage concentration at the target site, that is necessary for the desired levels of bacterial eradication. Also, worth mentioning is the necessity for phage preparations to be adequately purified (e.g., to remove bacterial debris). Such purification should be substantial (e.g., to remove most bacterial components, including endo-toxins), particularly when phages are to be delivered directly to an animal’s systemic circulation (Chan, Abedon, Loc-Carrillo, 2013).

Recently, the turn back to phage therapy has led the scientists to evaluate the pharmacokinetic efficacy of phage therapy. One such investigation was done in Phage Therapy Center at the Institute of Immunology and Experimental Therapy, the Polish Academy of Sciences. Scientists have examined the estimated cost of treating staphylococcal infection in which good clinical outcome of the bacteriophage therapy was shown. classicaly, the phages are delivered orally and/or locally in the form of phage lysates (Międzybrodżki et al., 2007). Moreover, the problem of phages to leave the blood stream and reach the infected tissues can be avoided by phage constructs with tissue-specific peptides, it will help the phages to reach the targeted organs (Górski et al., 2015).

Phage formulation is another important aspect of governing effective pharmacokinetics. Different formulation strategies are employed to increase the stability of phages. The no of active phages in a formulation is directly proportional to the efficacy of treatment. The table I summarize recent formulation strategies for the phage preparation.

**Routes of administration**

Various studies have been conducted on bacteriophage therapy to investigate the delivery routes, most studied being the parenteral and oral route of administration and both of them are systemic. On the other hand, non-systemic routes or local phage delivery systems are being investigated. The use of phage lysate for prevention of biofilm on medical equipment is also studied.

The varied concepts of pharmacokinetics – requirement for phage to penetrate the target bacteria, the accomplishment of adequate phage concentration in the locality of the target, and ample antibacterial action against the target – are worth considering when treating various infections in both animal models and humans.

**Bacteriophages via parenteral delivery**

In phage therapy, parenteral delivery has proven to be the most successful of all delivery regimes; this success is explained by the maximum distribution and bioavailability of the administered phages.

A study was conducted on mice compromised by burn injury and subsequently infected by *Pseudomonas aeruginosa*, the infected mice were treated with phage cocktail containing three different *P. aeruginosa* phages. Phages were given by three delivery routes; intramuscular, intravenous and intrasubcutaneous. The comparative
efficacies of these delivery routes were measured showing that the intravascular route provided the most significant defense against the infection (up to 87%). Moreover, the dosage quantity of given phage cocktail was also important in attaining improved pharmacokinetics, the high dosage of phages was more effective (McVay, Velásquesz, Fralick, 2007).

Phage movement from one body section to another can greatly hurdle effective therapy. The parenteral and oral dosing primarily results in blood circulation. The absorption is expected to be more proficient through the parenteral route, i.e. there is a probability of less phage loss in parenteral delivery as compared to oral delivery. With oral dosing, phages must endure and pass the gastrointestinal zone, both of which are not the simple course of action. On the other hand, topical application minimizes associated losses of absorption and distribution, enhancing antibacterial activity of phages. Instillation, i.e. directly injecting phages in infection sites also minimizes the losses, though it is more restrained than topical application (Figure 1). (Abedon, 2015).

Similarly, another study, using Liposomes as a delivery vehicle for phage for the first time, used the intraperitoneal (IP) route of administration to explain the therapeutic and prophylactic potential of bacteriophage in a mouse model of lobar pneumonia caused by K. pneumoniae (Singla et al., 2015).

A similar study conducted previously, in which Bacteremia was induced in mice by IP injection of a strain of vancomycin-resistant Enterococcus faecium. A single IP injection of phage strain ENB6 was administered after 45 min of infection. The survival rate was shown to be 100%.

TABLE I - Phage formulation strategies

<table>
<thead>
<tr>
<th>Formulation strategy</th>
<th>Phage type</th>
<th>Use</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liquid/ suspension</td>
<td>ZF40, ZF49, Phage T4, BFC-1 phage cocktail.</td>
<td>Wound dressing, injectable, food additives and nebulizers.</td>
<td>(Borie et al., 2009; Golshahi et al., 2008; Hoe et al., 2013; Merabishvili et al., 2009; Merabishvili et al., 2013)</td>
</tr>
<tr>
<td>Solid; Powdered, microencapsulation</td>
<td>KS14, N-1, S-204, Sh-1, KS-41, D3, F2, F-9, Felix01, cocktails</td>
<td>Inhalable powder, bandages, tablets, pills</td>
<td>(Hoe et al., 2013; Matinkhoo et al., 2011; Ohtake et al., 2010; Vandenheuvel et al., 2013)</td>
</tr>
<tr>
<td>Cream, oil-water emulsion</td>
<td>Staphylococcus phase K</td>
<td>Can be used as a topical, ointment</td>
<td>(Esteban et al., 2014; O’Flaherty et al., 2005)</td>
</tr>
<tr>
<td>PEGylated</td>
<td>Felix01</td>
<td>Injectable</td>
<td>(Veronese, Pasut, 2005)</td>
</tr>
<tr>
<td>Amino acid substitution</td>
<td>Agro1, Agro2, Agro3, Agro4, W60</td>
<td>Injectable</td>
<td>54</td>
</tr>
</tbody>
</table>

Most of the studies using P. aeruginosa delivered via the IP route suggested that the phages were rapidly distributed to the tissues and were delivered for a longer period of time than phages administered via the intrasubcutaneous or intramuscular route.

**Bacteriophages via oral delivery**

Bacteriophage delivery through oral administration suggests its success in treating gastrointestinal infection and, in rare cases systemic infections. The pathogen bacteria, which is located in the gut is mainly accessible...
to orally applied phages. However, there are drawbacks of
the oral delivery system; primarily it’s the deactivate ion of
bacteriophages by the acidic environment of stomach. The
sensitivity to the acidic environment varies for different
bacteriophages, for some deactivation may occur. Hence,
there is a need for the characterization of bacteriophage
individually.

The gastric acid neutralization is done with the
administration of some “stomach acid neutralizing agent”
like sodium bicarbonate or bicarbonated mineral water
(Qadir, 2015). Phages may be given orally three times a day
before eating, as the PH is slightly less acidic at this time.

Some orally applied phages are absorbed into
the circulation system. However, it depends on the
characteristics of each individual phage (Oliveira et
al., 2009). Some phages reside inside the gut lumen,
they are also absorbed through the intestinal walls. The
underlying mechanism of the viral translocation remain
unclear, it is recommended that the number of factors
control bacteriophage passage through intestinal walls,
for example, phage concentration, capsid protein’s specific
sequences for interaction with the intestinal cell membrane
and its interaction with immune cells within the gut.

For combating the problem of deactivation many
preventive strategies can be applied. One such method is
microencapsulation, for example, bacteriophage Felix O1
was microencapsulated in alginate-chitosan microsphere.
This encapsulation appreciably increased the acidic
endurance of phage under laboratory conditions designed
to replicate in the pig gastrointestinal tract (Ma et al., 2008).

Recent encapsulation strategies are aimed at
providing a delivery technology with improved efficacy of
bacteriophage in oral application. Enteric polymers have
been demonstrated to offer effective protection for bacteria
against in vitro simulated gastric conditions; likewise, they
might be used for the phage encapsulation.

Phage cocktail is another method to effectively
deliver bacteriophages via oral administration. In an
investigation, phage cocktail consisting of SP15, SP21
and SP22 bacteriophages was used against a strain of E.
coli, with the most successful administration route being
a daily oral dose of phages (Tanji et al., 2005).

Hence, studies show that bacteriophage can be
absorbed efficiently into systemic circulation through oral
administration. Nonetheless, absorption via oral delivery
depends on the individual characteristics of each phage
as well.

Local delivery of phages

The local delivery of phages is one of the successful
administration regimes, and several reports are present
in literature, most of them focusing wound healing.
There has been development of hydro-gel and saturated
formulations of bacteriophages for wound healing. It has
greatly increased the phage therapy’s success in topical
applications. Locally, phages can be applied on infected
areas in the form of moist dressing (Qadir, 2015).

A commercially successful example of topical
product is the Phagebioderm®, it was developed by the
Eliava Institute, Georgia. This formulation specifically
targets *P. aeruginosa*, *S. aureus* and *Streptococcus* spp. It
is a cocktail of antibiotics and bacteriophages saturated
in stabilized hydrogel arrangement for topical application
(Markoishvili et al., 1999). Currently, local phage
therapy has also focused on other areas i.e. otic and oral
applications.

**Topical administration of phages**

In topical form, the bacteriophage has been effective
for the treatment of skin ailments. A study has been
reported using bacteriophages to decrease the infection
of chicken skin by *Salmonella* and *Campylobacter* spp.
The MOI of phages were assessed i.e. the effect of the
ratio of phage particles to bacterial cells. Phages were
applied at two different MOI, one at relatively higher MOI
then other. The investigation showed that the efficiency
of phage treatment was dependent on phage quantity. By
increasing the MOI, increased bacterial eradication was
observed (Goode, Allen, Barrow, 2003).

A recent report investigated the efficacy of phages
against natural healing agents (aleovera and honey). The
*K. pneumoniae* B5055-induced burn wound infection
was treated with topical application of *Klebsiella*-specific
phage Kpn5, on the other hand, with aleovera and honey.
A survival rate of up to 96.66% observed with phage
treatment in comparison to the death rate of 83.34% in
the second group on the second day post treatment. One
interesting finding was that the treatment with high titre of
phage resulted in a long term solution to the infection and
the low titre was ineffective, hence sufficient concentration
of phages are crucial for the successful treatment (Kumari,
Harjai, Chhibber, 2010).

**Otic administration of phage**

Data is available from clinical trials of bacteriophage
therapy in chronic otitis caused by an extended spectrum
strain of *P. aeruginosa*. The patients studied with an ear
infection of *P. aeruginosa*. They were randomly divided
into two groups, one receiving a single dose of Biophage-
PA® and the second receiving placebo; the phages were given via otic administration. The patients followed up at 7, 21 and 42 days after treatment. It was shown that the administration of this topical bacteriophage mixture successfully killed *P. aeruginosa* in the ear and improved the clinical manifestation of ear infectivity (Wright et al., 2009). A latest study, reporting clinical trial on canine for the treatment of *P. aeruginosa* otitis with bacteriophage cocktail, holds similar assures. Hence, this topical bacteriophage formulation is a potential candidate to be conveniently and effectively used against *P. aeruginosa* otitis in dogs (Hawkins et al., 2010).

Furthermore, phages are used in the form of suspension (Drops) for application to eye, middle ear and nasal mucosa (Qadir, 2015).

### Dental phage administration

Number of papers and patent filing reports focus on the use of phages in combating dental infections. An investigation was carried out to assess the effect of bacteriophage on the viability of *Enterococcus faecalis* (ATTC 29212) in human dental roots. The teeth were divided in five groups, all were given different conc. of bacteriophages. A substantial reduction in bacterial growth was observed in all groups, which indicates the ability of phages to inhibit bacterial growth in teeth tubules. Hence phage therapy can be considered an alternative for root canal infection, which is otherwise intractable by conventional endodontic therapy (Paisano et al., 2004).

### Nebulizer inhalation of bacteriophage

The most recent advances in the field of phage therapy have been inhalation technologies. In view of the success of bacteriophage therapy in both local and systemic applications, using bacteriophages to fight lung infections look promising. The development of modern inhalation and process technologies has allowed great advances in this field. Recently, nebulizers have been introduced to deliver bacteriophages to the lungs. A study focused on the efficiency of nebulizer delivery and the particle-size distribution of droplets (Golshahi et al., 2008). The nebulizer was shown to be successfully delivered the phage particles to the lungs. Moreover, further examination of in-vitro delivery of bacteriophages using the inhalation formulation of dry powder was done by the same group of scientist for treatment of cystic fibrosis pulmonary infections (Golshahi et al., 2011).

Another study was done indicating in-vivo efficacy of phage therapy for *Burkholderia cepacia* lung infections. A mouse model of severe respiratory tract infection was used; the effect of treatment with a single phage strain on bacterial load and lung inflammation was examined. Mice were administered, either by intranasal inhalation or by IP injection. However, Bacterial concentration, macrophage inflammatory protein 2 (MIP-2) and tumor necrosis factor α (TNF-α) levels, were significantly reduced in the lungs of mice treated with IP-administered phages as compared to the inhalational administration (Carmody et al., 2010). A recent study suggests that *P. aeruginosa* isolated from the lungs of cystic fibrosis patients may become more susceptible, over the course chronic infections, to unassociated phages (Friman et al., 2013)

Many studies investigated the phage therapy against *Pseudomonas aeruginosa* in cystic fibrosis patients (James et al., 2015; Saussereau et al., 2014). The main element highlighted is the prospective of bacteriophage therapy in cystic fibrosis patients through inhalation. Certainly, the nebulizer route of administration is chosen for cystic fibrosis patients (Hraiech, Brégeon, Rolain, 2015).

### Instillation of phages

A case study recently reported the treatment of a 67-year old woman through instillation of phage formulation to the bladder. The patient was hospitalized and 20 ml Pyophage #051007 was instilled directly into the bladder for 10 days with 12 h gap, with the catheter fasten for half an hour after each instillation. The data indicated that bacteriophage infection was self-sustaining and self-limiting, with the phage decreasing in number alongside the viable target organisms in which they replicated (Khawaldeh et al., 2011).

### Elimination

After intraperitoneal administration, the level of bacteriophages decreased rapidly in first 8 to 12 hours and then gradually decreased and eventually disappeared in three days, depicts a pattern just like of two-compartmental model. The initial phase of the rapid decrease from 8 to 12 hours (considered as alpha-phase) is due to distribution of phages to the organs and second phase (considered as beta phase) is due to elimination of phages (Uchiyama et al., 2009). Although, the kinetics of blood clearance have had not been well described. So, for further development in therapeutic efficacy, information on bacteriophage blood kinetics is one of the most important criteria to determine optimal therapeutic approach.

Within 2 to 4 hours, a single oral dose results in the absorption of phages into the blood stream and to inner
According to the data available, phages reside in human body and circulating system for a substantial time period. It was determined that reticulo-endothelial system is involved in elimination of bacteriophages from the human body. However, the possible role of innate immunity on elimination of bacteriophages is not clear.

**CONCLUSION**

Phage therapy is a promising alternative for the inadequacy of antibiotics and their ever-decreasing effectiveness. It is evident, from a vast amount of research on phage therapy against various bacterial diseases, that phage provides a stronger shield against stubborn resistant pathogen bacterial strains. They were assumed to be therapeutic due to their bactericidal activity by replication within the target host; this unique pharmacokinetic property of being self-replicating drug gives it a preference over other antibiotics and chemical drugs. Moreover, many phages have been isolated against these extended spectrum strains and patented. The different delivery routes are effective depending upon the target tissues or organ. For example, the oral phage delivery is useful for the treatment GI tract infections, for skin infection, the topical phage application is a suitable and pulmonary bacterial disease can be efficiently treated with the inhalation of phage nebulizer. The most effective, in terms of therapeutic advantage, is the parenteral route of administration, as it provides direct distribution and maximum absorption. However, there has been a little data available on the pharmacokinetic profiling of phage formulations that are being used or are waiting for approval. The pharmacokinetic factors like formulation and concentration are well elaborated in literature; on the other hand, convenient and effective administrative routes require to be explained through further research. Furthermore, to benefit the full from tiny phage particles the factors like kinetics of blood clearance must to be addressed.

**TABLE II - Administration routes of phage therapy adapted in different pre-clinical and case study in humans**

<table>
<thead>
<tr>
<th>Administration route</th>
<th>Against</th>
<th>Results</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intramuscular</td>
<td>Meningitis in calves and <em>E. coli</em> septicaemia in chickens</td>
<td>Significant protection against <em>E. coli</em></td>
<td>(Barrow, Lovell, Berchieri, 1998)</td>
</tr>
<tr>
<td>Intravenous</td>
<td>Local and systemic disease caused by <em>Vibrio vulnificus</em> and <em>S. aureus</em> in animals</td>
<td>Phage treatment was radically reduced inflammation due to infection</td>
<td>(Abedon et al., 2011) (Capparelli et al., 2007)</td>
</tr>
<tr>
<td>intra-peritoneally</td>
<td>lethal <em>Staphylococcus aureus</em> infection in mice</td>
<td><em>S. aureus</em>-induced lethality Suppressed</td>
<td>(Matsuzaki et al., 2003)</td>
</tr>
<tr>
<td>Subcutaneous</td>
<td>Lung abscesses in rabbits and bronchiectasis <em>Staphylococcus aureus</em>, <em>Proteus</em>, and <em>Streptococci</em></td>
<td>92% survival was reported</td>
<td>(Wills, Kerrigan, Soothill, 2005) (Sakandelidzé, Meipariani, 1974)</td>
</tr>
<tr>
<td>Oral delivery</td>
<td>gastrointestinal infections and and rare cases of systemic infections</td>
<td>Titres of <em>E. coli</em> were significantly reduced</td>
<td>(Tanji et al., 2005)</td>
</tr>
<tr>
<td>Topical administration</td>
<td>Skin infection. <em>K. pneumoniae</em> induced burn wound infection in mice</td>
<td>Up to 90 % survival rate as compared to control group</td>
<td>(Kumari, Harjai, Chhibber, 2010)</td>
</tr>
<tr>
<td>Otic route</td>
<td>chronic otitis infection of extended spectrum <em>P. aeruginosa</em></td>
<td><em>P. aeruginosa</em> counts were significantly lower in the phage-treated group</td>
<td>(Wright et al., 2009)</td>
</tr>
<tr>
<td>Dental route</td>
<td><em>Enterococcus faecalis</em> infection human dental Roots</td>
<td>Reduce bacterial growth and number in root canal</td>
<td>(Paisano et al., 2004)</td>
</tr>
<tr>
<td>Inhalation</td>
<td><em>Pseudomonas Staphylococcus</em> and lung infections</td>
<td>50% reduction in required ongoing antibiotic treatment</td>
<td>(Golshahi et al., 2008; Kvachadze et al., 2011)</td>
</tr>
</tbody>
</table>
REFERENCES


Received for publication on 19th June 2017
Accepted for publication on 30th September 2017